CADL

CADL

USD

Candel Therapeutics Inc. Common Stock

$5.130+0.100 (1.988%)

Precio en Tiempo Real

Healthcare
Biotecnología
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$5.030

Máximo

$5.270

Mínimo

$5.030

Volumen

0.50M

Fundamentos de la Empresa

Capitalización de Mercado

281.6M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

0.77M

Bolsa

NGM

Moneda

USD

Rango de 52 Semanas

Mínimo $3.785Actual $5.130Máximo $14.6

Noticias Relacionadas

GlobeNewswire

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and CEO, will present the phase 3 clinical trial of

Ver más
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
GlobeNewswire

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies

Ver más
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
Analyst Upgrades

Stephens & Co. Initiates Coverage On Candel Therapeutics with Overweight Rating, Announces Price Target of $15

Stephens & Co. analyst Sudan Loganathan initiates coverage on Candel Therapeutics with a Overweight rating and announces Price Target of $15.

Ver más
Stephens & Co. Initiates Coverage On Candel Therapeutics with Overweight Rating, Announces Price Target of $15
Analyst Upgrades

LifeSci Capital Initiates Coverage On Candel Therapeutics with Outperform Rating, Announces Price Target of $16

LifeSci Capital initiates coverage on Candel Therapeutics with a Outperform rating and announces Price Target of $16.

Ver más
LifeSci Capital Initiates Coverage On Candel Therapeutics with Outperform Rating, Announces Price Target of $16